Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akari Therapeutics PLC AKTX

Healthcare Biotechnology
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

Recent & Breaking News (NDAQ:AKTX)

AKARI THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akari Therapeutics, Plc - (AKTX)

PR Newswire June 2, 2017

URGENT: Monteverde & Associates PC Invites Akari Therapeutics, Plc. Shareholders with Significant Losses To Contact The Firm Immediately - AKTX

PR Newswire June 1, 2017

Akari Therapeutics Announces Resignation of CEO

Business Wire May 30, 2017

Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc., Intra-Cellular Therapies, Inc. and Twilio Inc.

PR Newswire May 30, 2017

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

GlobeNewswire May 25, 2017

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against United States Steel Corporation (X) and Lead Plaintiff Deadline: July 3, 2017

GlobeNewswire May 25, 2017

SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

GlobeNewswire May 23, 2017

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Akari Therapeutics, Plc to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit

Business Wire May 23, 2017

AKTX LOSS NOTICE: Rosen Law Firm Reminds Akari Therapeutics, Plc Investors of Important Deadline in Class Action - AKTX

Business Wire May 23, 2017

IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

PR Newswire May 22, 2017

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Akari Therapeutics, Plc To Contact The Firm

PR Newswire May 22, 2017

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

PR Newswire May 19, 2017

SHAREHOLDER ALERT:  Pomerantz Law Firm Announces the Filing of a Class Action against Akari Therapeutics plc and Certain Officers – AKTX

GlobeNewswire May 19, 2017

How These Generic Drugs Stocks are Faring? -- MYOS RENS Technology, Akari Therapeutics, Flexion Therapeutics, and Zynerba Pharma

PR Newswire May 19, 2017

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

PR Newswire May 18, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Intra-Cellular Therapies, Inc. (ITCI) and Lead Plaintiff Deadline: July 11, 2017

GlobeNewswire May 18, 2017

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Akari Therapeutics, Plc and Advises Investors With Losses to Contact the Firm

Business Wire May 15, 2017

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Akari Therapeutics, Plc (Nasdaq: AKTX) To Contact Brower Piven Before The Lead Plaintiff Deadline

GlobeNewswire May 15, 2017

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

Business Wire May 15, 2017

The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akari Therapeutics, Plc Investors and Encourages Investors to Contact the Firm

Business Wire May 15, 2017